Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Fineline Cube Jun 30, 2026
Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Fineline Cube Jun 30, 2026
Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Fineline Cube Jun 30, 2026
Company Deals

Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration

Fineline Cube Jun 30, 2026
Company Deals

Merck Partners with ADAP Crisis Task Force to Expand Access to Idvynso HIV Treatment – Two-Drug Regimen Targets Virologically Suppressed Patients

Fineline Cube Jun 30, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Fineline Cube Jun 30, 2026
Company Drug

AbbVie and Genmab’s Epcoritamab-Lenalidomide Combination Achieves Primary Endpoint in Phase 3 DLBCL Trial – 60% Reduction in Progression/Death Risk vs Standard R-GemOx

Fineline Cube Jun 30, 2026
Company Deals

Shanghai Huikai Medical Technology Secures Series A+ Funding for Prostate Stent System

Fineline Cube Apr 19, 2023

Shanghai Huikai Medical Technology Co., Ltd, a China-based urology device manufacturer, has reportedly raised tens...

Company Drug

Shandong Jincheng Pharmaceutical Initiates Phase II Study for LT-01 Antibacterial Drug

Fineline Cube Apr 19, 2023

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233), China’s largest cephalosporin manufacturer, has announced receiving...

Company Deals

RemeGen Ltd Partners with Shandong Cancer Hospital for ADC Development and Integrated System

Fineline Cube Apr 19, 2023

RemeGen Ltd (HKG: 9995) has announced a strategic partnership with Shandong Cancer Hospital to establish...

Company Deals R&D

Nona Biosciences Partners with Dr. Michael S. Diamond for Viral Disease Monoclonal Antibody Research

Fineline Cube Apr 19, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates in the...

Company Deals

Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China

Fineline Cube Apr 19, 2023

China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...

Company Drug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...

Medical Device Policy / Regulatory

National Center Reports Increase in Medical Device Adverse Event Reports for 2022

Fineline Cube Apr 19, 2023

The National Center for Adverse Event Monitoring has released its national annual report regarding the...

Policy / Regulatory

China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog

Fineline Cube Apr 19, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Deals

China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab

Fineline Cube Apr 19, 2023

China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...

Company Drug

XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor

Fineline Cube Apr 19, 2023

XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment...

Company Drug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...

Company Drug

BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination

Fineline Cube Apr 18, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...

Company Drug

HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein

Fineline Cube Apr 18, 2023

Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a...

Company Deals

Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China

Fineline Cube Apr 18, 2023

The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership...

Company Deals

Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing

Fineline Cube Apr 18, 2023

Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions...

Company Drug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

Fineline Cube Apr 18, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Apr 18, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Drug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

Fineline Cube Apr 18, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...

Company

CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts

Fineline Cube Apr 18, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...

Company Deals

PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion

Fineline Cube Apr 18, 2023

China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...

Posts pagination

1 … 558 559 560 … 688

Recent updates

  • METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company
  • Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China
  • Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
  • Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications
  • Anhui Wanbang Pharmaceutical to Acquire 75.52% Stake in CRO CTSMED for RMB 302M – Expands Clinical Research Capabilities Through Strategic Vertical Integration
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

METiS TechBio Signs Record $1.62B Global Licensing Deal for AI-Designed Tri-Specific TCE MTS-128 – Largest Preclinical TCE Out-Licensing by Chinese Pharma Company

Company Deals

Eli Lilly Partners with Innovent Biologics on Verzenio CDK4/6 Inhibitor – Chinese Biotech Secures Exclusive Commercialization Rights in Mainland China

Company Deals

Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline

Company Drug

Shanghai Bao Pharmaceuticals Secures NMPA IND Approval for BJ044 Recombinant Ulinastatin – First Synthetic Biology-Derived Therapy for Critical Care Indications

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.